

MEDIA RELEASE

NEWS FROM THE UNIVERSITY OF TASMANIA

DATE: FRIDAY 5 SEPTEMBER 2008

ATTENTION: Chiefs of Staff, News Directors



Separation science comes together at new \$4.6 million research facility

A new \$4.6 million centre of excellence at the University of Tasmania will position the School of Chemistry as a leader in pharmaceutical drug discovery.

The collaborative research facility will be officially opened by the Premier David Bartlett today and is a joint investment by the world's largest research-based pharmaceutical company Pfizer, the State Government and the University of Tasmania.

The Pfizer Analytical Research Centre (PARC), Hobart, will drive cutting-edge advancements in the production and quality of safe pharmaceutical drugs, in partnership with the PARC centre at Belgium's Ghent University.

PARC Hobart Director, Professor Paul Haddad, said the collaboration between Pfizer scientists and the University's Australian Centre for Research on Separation Science (ACROSS) team was a significant initiative.

"The collaboration will provide a direct link between experts in analytical chemistry and the pharmaceutical industry," Prof Haddad said.

- **When:** Friday 5 September, 10am (event finishes at 10.40am).
- **Who:** Tasmanian Premier David Bartlett
Prof Paul Haddad, Director, Pfizer Analytical Research Centre (Hobart)
Mr John Latham, Regional Director, Pfizer Australia and New Zealand
- **Where:** Room 321, School of Chemistry Building (Level 3), Dobsons Rd, Sandy Bay campus.

For more information or interviews contact:

Pfizer Analytical Research Centre, Director, Prof Paul Haddad

Ph: (03) 6226 2179

Pfizer Analytical Research Centre, Deputy Director, Dr Greg Dicoski

Ph: (03) 6226 2166

Information released by:

The Media Office, University of Tasmania

Phone: 03 6226 2124 (Hobart) or 03 6324 3218 (Launceston)

Mobile: 0417 517 291

Email: Media.Office@utas.edu.au